Simulations Plus, Inc. (NASDAQ:SLP) Given Consensus Rating of “Moderate Buy” by Analysts

Simulations Plus, Inc. (NASDAQ:SLP) has received a consensus recommendation of “Moderate Buy” from the five ratings firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $56.00.

Several research firms recently weighed in on SLP. Craig Hallum restated a “buy” rating and issued a $56.00 target price on shares of Simulations Plus in a report on Wednesday, July 3rd. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a report on Thursday, September 12th. BTIG Research decreased their price target on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a report on Thursday. KeyCorp started coverage on Simulations Plus in a research note on Monday, July 29th. They issued an “overweight” rating and a $47.00 price objective on the stock. Finally, JMP Securities initiated coverage on Simulations Plus in a research note on Tuesday, July 16th. They set a “market perform” rating for the company.

Insider Transactions at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $35.18, for a total value of $703,600.00. Following the completion of the sale, the director now owns 3,501,592 shares in the company, valued at approximately $123,186,006.56. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders have sold 60,750 shares of company stock worth $2,145,055. 20.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Simulations Plus

Hedge funds have recently made changes to their positions in the business. Azzad Asset Management Inc. ADV raised its position in Simulations Plus by 3.6% in the second quarter. Azzad Asset Management Inc. ADV now owns 8,007 shares of the technology company’s stock worth $389,000 after purchasing an additional 280 shares in the last quarter. InTrack Investment Management Inc boosted its stake in Simulations Plus by 1.1% in the 2nd quarter. InTrack Investment Management Inc now owns 31,665 shares of the technology company’s stock valued at $1,540,000 after buying an additional 330 shares in the last quarter. Chatham Capital Group Inc. grew its position in Simulations Plus by 1.3% in the second quarter. Chatham Capital Group Inc. now owns 34,554 shares of the technology company’s stock valued at $1,680,000 after acquiring an additional 450 shares during the period. The Manufacturers Life Insurance Company raised its stake in Simulations Plus by 7.7% during the second quarter. The Manufacturers Life Insurance Company now owns 6,391 shares of the technology company’s stock worth $311,000 after acquiring an additional 456 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Simulations Plus by 5.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,048 shares of the technology company’s stock valued at $414,000 after acquiring an additional 562 shares during the period. Institutional investors and hedge funds own 78.08% of the company’s stock.

Simulations Plus Stock Performance

Shares of Simulations Plus stock traded down $2.82 during midday trading on Thursday, reaching $31.16. 317,875 shares of the company’s stock traded hands, compared to its average volume of 127,421. Simulations Plus has a 52 week low of $29.37 and a 52 week high of $51.22. The company’s 50 day simple moving average is $33.31 and its 200 day simple moving average is $40.83. The company has a market cap of $623.51 million, a price-to-earnings ratio of 65.96 and a beta of 0.69.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.